Biotron Ltd has released a press release.
BIT225 Phase 2 HIV-1 Clinical Trial Fully Recruited
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Biotron
- Positive FDA guidance for covid-19 clinical program
- BIT225 effective against established sars-cov-2 in animals
- Quarterly Cash Flow Report Appendix 4C
- Quarterly Activities Report
- $1.56M R&D Rebate Received
Later from Biotron
- Bit225 Covid-19 Human Study Commenced
- Second BIT225 Phase 2 HIV-1 Clinical Trial Fully Recruited
- Renounceable Issue
- Commencement of Rights Trading - BITRC
- $1.43M R&D rebate received
Follow Biotron into a list and get an email when it puts out news.
Follow Biotron